We have updated our Terms of Use.
Please read our new Privacy Statement before continuing.

New name, same Valeant

8 May 2018 By Robert Cyran

The drugmaker that fell from grace in 2015 says it has turned over a new leaf. It’s renaming itself, touting a return to organic growth and reducing borrowing. Behind the gloss and a raft of footnotes, though, is $25 bln of net debt atop a $7 bln firm with declining prospects.

This content is for Subscribers only


Email a friend

Please complete the form below.

Required fields *


(Separate multiple email addresses with commas)